Prescription Drug Affordability and Access Act
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Prescription Drug Affordability and Access Act (S.4845) is a Senate bill introduced in the 118th Congress aimed at addressing issues related to the affordability and accessibility of prescription drugs. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on July 30, 2024. However, the bill ultimately failed or expired without further legislative action. No official summary or full text of the bill is available in the source data, limiting detailed analysis of its provisions.
S.4845 sought to improve prescription drug affordability and access but did not advance beyond committee referral and expired without enactment.
- The bill was introduced in the Senate during the 118th Congress and referred to the Health, Education, Labor, and Pensions Committee.
- No official summary or full text is available, so specific policy mechanisms or provisions cannot be analyzed.
- The bill status is marked as failed or expired, indicating it did not pass into law.
Potential beneficiaries would likely include patients requiring prescription medications, healthcare providers, and possibly government health programs, though specific beneficiaries cannot be identified due to lack of detailed bill text.
Without the full text or summary, potential concerns include unknown implementation challenges, funding requirements, enforcement mechanisms, and oversight provisions that could affect effectiveness and administrative burden.
The bill was introduced in the Senate and referred to a key committee overseeing health policy but did not progress further. This reflects the legislative process where many bills are introduced but do not advance to become law. The policy area of health and prescription drug affordability is a recurring topic in congressional discussions.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
If enacted, the bill could have influenced prescription drug pricing, healthcare costs, and patient access to medications. Its failure to pass means these potential effects were not realized. The legislative effort may inform future proposals on drug affordability.
Transparency is limited due to missing official summary and full text, which are essential for public understanding and oversight. The bill's failure to advance highlights the importance of tracking legislative progress and ensuring access to complete bill documentation for accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.